Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Reviva Pharmaceuticals Holdings's enterprise value is $-16.06 Mil.
Reviva Pharmaceuticals Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-16.60 Mil. Therefore, Reviva Pharmaceuticals Holdings's EV-to-EBITDA for today is 0.97.
The historical rank and industry rank for Reviva Pharmaceuticals Holdings's EV-to-EBITDA or its related term are showing as below:
RVPH'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.98
Current: 0.97
During the past 7 years, the highest EV-to-EBITDA of Reviva Pharmaceuticals Holdings was 0.98. The lowest was 0.00. And the median was 0.00.
RVPH's EV-to-EBITDA is ranked better than 79.35% of 402
companies
in the Biotechnology industry
Industry Median: 13.3
vs RVPH: 0.97
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Reviva Pharmaceuticals Holdings's PE Ratio (TTM) for today is calculated as:
Reviva Pharmaceuticals Holdings's share price for today is $0.45.
Reviva Pharmaceuticals Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.633.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Reviva Pharmaceuticals Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Reviva Pharmaceuticals Holdings EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Reviva Pharmaceuticals Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Reviva Pharmaceuticals Holdings's EV-to-EBITDA falls into.
Reviva Pharmaceuticals Holdings's current Enterprise Value is $-16.06 Mil.
Reviva Pharmaceuticals Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Reviva Pharmaceuticals Holdings (RVPH) has a EV-to-EBITDA of 0.97 as of Aug. 11, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Reviva Pharmaceuticals Holdings. According to the industry distribution chart, Reviva Pharmaceuticals Holdings ranks #83 out of 402 companies in the Biotechnology industry, placing it in the top 20.6%.
Is Reviva Pharmaceuticals Holdings' EV-to-EBITDA too high?
Reviva Pharmaceuticals Holdings' current EV-to-EBITDA is 0.97. The Biotechnology industry median EV-to-EBITDA is 13.30. Reviva Pharmaceuticals Holdings' value of 0.97 is 92.7% below this industry median. Based on the distribution chart, Reviva Pharmaceuticals Holdings ranks #83 out of 402 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Reviva Pharmaceuticals Holdings has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Reviva Pharmaceuticals Holdings' EV-to-EBITDA compare to CVKD and ACXP?
According to the Biotechnology industry distribution chart, Reviva Pharmaceuticals Holdings ranks #83 out of 402 companies for EV-to-EBITDA. This places Reviva Pharmaceuticals Holdings in the top 21% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.30. Reviva Pharmaceuticals Holdings' value of 0.97 is 92.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.30, based on 402 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Reviva Pharmaceuticals Holdings's current EV-to-EBITDA of 0.97 is 92.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Reviva Pharmaceuticals Holdings. For the Biotechnology industry, the median EV-to-EBITDA is 13.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Reviva Pharmaceuticals Holdings's current EV-to-EBITDA is 0.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Reviva Pharmaceuticals Holdings stock overvalued right now?
Reviva Pharmaceuticals Holdings (RVPH) has a current EV-to-EBITDA of 0.97. The current EV-to-EBITDA is 0.97 and 92.7% below the Biotechnology industry median of 13.30. Reviva Pharmaceuticals Holdings' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Reviva Pharmaceuticals Holdings (RVPH), the current EV-to-EBITDA is 0.97 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063), which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis, and its other drug candidate is RP1208.
22GF Score
Get the complete analysis for RVPH
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RVPH has been successfully added to your 
